Drugs / Piperacillin/tazobactam
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT06422533 Comparator | Nov 2023 → Jul 2025 | hematopoietic and lymphoid cell neoplasm, neutropenia | National Cancer Institute of Mexico | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piperacillin/tazobactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06422533 ↗ |
| Route | Intravenous | “Piperacillin/tazobactam 4.5 g qid IV infusion for 30 minutes during 5 to 7 days” NCT06422533 ↗ |